In the last trading session, 3.36 million Xilio Therapeutics Inc (NASDAQ:XLO) shares changed hands as the company’s beta touched -0.24. With the company’s per share price at $0.93 changed hands at -$0.13 or -12.26% during last session, the market valuation stood at $42.55M. XLO’s last price was a discount, traded about -107.53% off its 52-week high of $1.93. The share price had its 52-week low at $0.53, which suggests the last value was 43.01% up since then.
Analysts gave the Xilio Therapeutics Inc (XLO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended XLO as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Instantly XLO was in red as seen at the end of in last trading. With action -27.91%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -2.62%, with the 5-day performance at -27.91% in the red. However, in the 30-day time frame, Xilio Therapeutics Inc (NASDAQ:XLO) is 4.48% up.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 86.71% from its current market value. According to analyst projections, XLO’s forecast low is 7 with 7 as the target high. To hit the forecast high, the stock’s price needs a -652.69% plunge from its current level, while the stock would need to soar -652.69% for it to hit the projected low.
Xilio Therapeutics Inc (XLO) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -44.91%. The 2025 estimates are for Xilio Therapeutics Inc earnings to increase by 59.04%, but the outlook for the next 5-year period is at 39.65% per year.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
ROCK SPRINGS CAPITAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 10.7595% or 3.0 million shares worth $2.85 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund. With 739.56 shares estimated at $0.69 million under it, the former controlled 1.68% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.41% of the shares, roughly 180.18 shares worth around $0.17 million.
